Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ.
Location: United States, Massachusetts, Norwood
Employees: 51-200
Phone: +1 617-963-0100
Total raised: $25M
Founded date: 2014
Investors 3
Funding Rounds 1
Date | Series | Amount | Investors |
30.01.2018 | - | $25M | - |
Mentions in press and media 8
Date | Title | Description | Source |
12.03.2024 | Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2... | - | globenewsw... |
06.03.2024 | Corbus Pharmaceuticals to Participate in the BMO Capital Mar... | - | globenewsw... |
12.11.2021 | Corbus Pharmaceuticals Reports Third Quarter 2021 Financial ... | NORWOOD, Mass., Nov. 12, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (... | marketscre... |
24.08.2020 | CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceutical... | Corbus Pharmaceuticals Holdings, Inc. Quarterly Update Conference Call and Webcast November 8, 2018 ... | marketscre... |
13.08.2020 | CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceutical... | Corbus Pharmaceuticals Holdings Second Quarter Earnings Conference Call August 6, 2020 Page 1 of 14 ... | marketscre... |
26.07.2019 | Peer Review: Rubius recruits BD chief; Epizyme hires Nov... | Kris Elverum → Rubius Therapeutics — clinical-stage biopharmaceutical company develop... | endpts.com... |
30.01.2018 | Corbus scores $25M from Cystic Fibrosis Foundation for 415-p... | Corbus Pharmaceuticals has bagged $25 million from the Cystic Fibrosis Foundation, which will carry ... | fiercebiot... |
27.10.2017 | Biotech Peer Review: Magenta onboards five new VPs; BioI... | → Following a $50 million series B in April, stem cell transplantation startup Magenta The... | endpts.com... |